Table 2 Weighted logistic regression analyses of the relationship between NAFLD/MAFLD/MASLD and FIB-4 and HSI scores in the studied population.

From: Comparison of prevalence of fatty liver disease according to the different nomenclatures of NAFLD, MAFLD, and MASLD in a large Iranian Population-based study

Nominations of FLD

FIB-4

HSI

Model 1

Model 2

Model 3

Model 1

Model 2

Model 3

Non-NAFLD

Ref

Ref

NAFLD

2.16(1.94–2.41), 0.001

1.87(1.64–2.13), 0.001

1.45(1.25–1.68), 0.001

1.24(1.23–1.25), 0.001

1.23(1.22–1.24), 0.001

1.10(1.08–1.12), 0.001

Non-MAFLD

Ref

Ref

MAFLD

1.77(1.49–2.10), 0.001

2.25(2.00–2.54.00.54), 0.001

2.01(1.82–2.21), 0.001

1.55(1.52–1.57), 0.001

1.58(1.55–1.61), 0.001

1.27(1.24–1.30), 0.001

Non-MASLD

Ref

Ref

MASLD

2.16(1.94–2.41), 0.001

1.87(1.64–2.13), 0.001

1.45(1.25–1.68), 0.001

1.24(1.23–1.25), 0.001

1.23(1.22–1.24), 0.001

1.10(1.08–1.12), 0.001

  1. Data were presented as odds ratios (OR) and 95% confidence intervals (95% CI).
  2. For all definitions: Model 1: crude, Model 2: adjusted for age (years) and gender(men/women), Model 3: adjusted for age (years), gender (men/women), smoking (yes/no), physical activity (METs/day), and BMI (kg/m2).
Back to article page